Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing transformative therapies for cancer and rare diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management will deliver a presentation on Thursday, January 16, 2025, at 7:30 am PT in San Francisco.
The presentation will be accessible through a live webcast on the Events and Presentations section of Protara's investor relations website at https://ir.protaratx.com. Interested parties who cannot attend in person can view the presentation online, and a recording will be available for a time afterward.
Protara Therapeutics (Nasdaq: TARA), una compagnia in fase clinica focalizzata nello sviluppo di terapie trasformative per il cancro e le malattie rare, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Il management della compagnia terrà una presentazione giovedì 16 gennaio 2025, alle 7:30 ora del Pacifico a San Francisco.
La presentazione sarà accessibile tramite un webcast dal vivo nella sezione Eventi e Presentazioni del sito web delle relazioni con gli investitori di Protara all'indirizzo https://ir.protaratx.com. Le parti interessate che non possono partecipare di persona possono visualizzare la presentazione online, e una registrazione sarà disponibile per un periodo di tempo successivo.
Protara Therapeutics (Nasdaq: TARA), una empresa en etapa clínica centrada en desarrollar terapias transformadoras para el cáncer y enfermedades raras, ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare. La dirección de la empresa realizará una presentación el jueves 16 de enero de 2025, a las 7:30 am PT en San Francisco.
La presentación será accesible a través de una transmisión en vivo en la sección de Eventos y Presentaciones del sitio web de relaciones con inversores de Protara en https://ir.protaratx.com. Las partes interesadas que no puedan asistir en persona podrán ver la presentación en línea, y una grabación estará disponible por un tiempo después.
Protara Therapeutics (Nasdaq: TARA)는 암 및 희귀 질환에 대한 혁신적인 치료법 개발에 집중하는 임상 단계 회사로, 제43회 연례 J.P. Morgan 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2025년 1월 16일 목요일 오전 7:30 PT에 샌프란시스코에서 발표를 진행할 예정입니다.
이 발표는 Protara의 투자자 관계 웹사이트의 이벤트 및 발표 섹션에서 생중계로 접속할 수 있습니다. 직접 참석할 수 없는 관심 있는 분들은 온라인으로 발표를 시청할 수 있으며, 이후 일정 기간 동안 녹화본도 제공될 예정입니다.
Protara Therapeutics (Nasdaq: TARA), une entreprise en phase clinique axée sur le développement de thérapies transformatrices pour le cancer et les maladies rares, a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare. La direction de l'entreprise fera une présentation jeudi 16 janvier 2025 à 7h30 PT à San Francisco.
La présentation sera accessible via un webcast en direct dans la section Événements et Présentations du site web des relations investisseurs de Protara à l'adresse https://ir.protaratx.com. Les personnes intéressées qui ne peuvent pas assister en personne peuvent visionner la présentation en ligne, et un enregistrement sera disponible pendant un certain temps par la suite.
Protara Therapeutics (Nasdaq: TARA), ein Unternehmen in der klinischen Phase, das sich auf die Entwicklung transformativer Therapien für Krebs und seltene Erkrankungen konzentriert, hat seine Teilnahme an der 43. J.P. Morgan Healthcare Konferenz angekündigt. Das Management des Unternehmens wird am Donnerstag, den 16. Januar 2025, um 7:30 Uhr PT in San Francisco eine Präsentation halten.
Die Präsentation wird über ein Live-Webcast im Bereich Veranstaltungen und Präsentationen auf der Investor Relations-Website von Protara unter https://ir.protaratx.com zugänglich sein. Interessierte, die nicht persönlich teilnehmen können, haben die Möglichkeit, die Präsentation online anzusehen, und eine Aufzeichnung wird für eine gewisse Zeit danach verfügbar sein.
- None.
- None.
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 7:30 am PT in San Francisco.
A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
When is Protara Therapeutics (TARA) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Protara Therapeutics' (TARA) J.P. Morgan Healthcare Conference presentation?
Will Protara Therapeutics' (TARA) J.P. Morgan Healthcare Conference presentation be available for replay?
What therapeutic areas does Protara Therapeutics (TARA) focus on?
